{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:23:39Z","timestamp":1788276219290,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph\n                      <jats:sup>+<\/jats:sup>\n                      MPAL) is a rare and aggressive hematologic malignancy. The incorporation of tyrosine kinase inhibitors (TKIs) into acute lymphoblastic leukemia (ALL)-like regimens has improved survival for Ph\n                      <jats:sup>+<\/jats:sup>\n                      MPAL. However, the benefit of ALL-like chemotherapy backbones for adult patients, particularly those with bilineal disease, appears limited and is often hampered by significant toxicity. To the best of our knowledge, this case adds to the limited clinical experience regarding the use of azacitidine, venetoclax, and dasatinib in Ph\n                      <jats:sup>+<\/jats:sup>\n                      MPAL. Novel, safer strategies are urgently needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 32-year-old man presented with a one-week history of fever. Bone marrow examination revealed 83% blasts with two distinct populations: lymphoblasts and monoblasts, confirming bilineal B\/myeloid MPAL. Karyotyping showed 45, XY,\u22127, t(9;22)(q34;q11.2), and the\n                      <jats:italic>BCR::ABL<\/jats:italic>\n                      (p190) fusion gene was positive. Molecular genetics identified an EVI1 fusion gene and an ASXL1 mutation. The patient received one cycle of induction therapy with azacitidine, venetoclax, and dasatinib, augmented with Vincristine, prednisone, and homoharringtonine. Complete remission was achieved following this cycle, with the primary adverse event being grade IV myelosuppression, managed without severe infection, tumor lysis syndrome or organ dysfunction. After three consolidation cycles, flow cytometry showed negative minimal residual disease (MRD); however,\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      remained detectable at 0.3289%. The patient subsequently underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT). At the most recent follow-up,\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      was undetectable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      An induction regimen based on azacitidine, venetoclax, and dasatinib may represent a safe and effective therapeutic strategy for adult patients with Ph\n                      <jats:sup>+<\/jats:sup>\n                      , bilineal MPAL, particularly when augmented with agents targeting distinct lineage components.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1788083","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:00:20Z","timestamp":1788274820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful induction of remission with azacitidine, venetoclax, and dasatinib followed by allogeneic hematopoietic stem cell transplantation in a patient with Philadelphia chromosome-positive mixed phenotype acute leukemia (B\/myeloid): a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Juan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Shenzhen Hospital of Southern Medical University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Shenzhen Integrated Traditional Chinese and Western Medicine Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangkui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Hospital of Southern Medical University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaikai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Hospital of Southern Medical University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Hospital of Southern Medical University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3390\/cancers17050871","article-title":"Acute leukemia of ambiguous lineage: diagnosis and evaluation by flow cytometry","volume":"17","author":"Fuda","year":"2025","journal-title":"Cancers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood.2022019493","article-title":"The International Consensus Classification of acute leukemias of ambiguous lineage","volume":"141","author":"Weinberg","year":"2023","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/hematology.2024000554","article-title":"How to think about acute leukemia of ambiguous lineage","volume":"2024","author":"Weinberg","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/blood-2017-12-821363","article-title":"International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia","volume":"132","author":"Hrusak","year":"2018","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/10428194.2019.1697813","article-title":"Complete measurable residual disease response after combination chemotherapy with AML-type and ALL-type regimens in pediatric B\/myeloid acute bilineal leukemia","volume":"61","author":"Saito","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1623528","DOI":"10.3389\/fonc.2025.1623528","article-title":"Philadelphia chromosome-positive mixed-phenotype acute leukemia: a case report and literature review","volume":"15","author":"Yang","year":"2025","journal-title":"Front Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/ajh.25873","article-title":"Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome","volume":"95","author":"Qasrawi","year":"2020","journal-title":"Am J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/mco.2021.2466","article-title":"Hypocellular Philadelphia chromosome-positive mixed-phenotype acute leukemia successfully treated with dasatinib: a case report","volume":"16","author":"Lee","year":"2022","journal-title":"Mol Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"107311","DOI":"10.1016\/j.leukres.2023.107311","article-title":"Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia","volume":"130","author":"Atchley","year":"2023","journal-title":"Leuk Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR::ABL1 tyrosine kinase inhibitor combinations: outcome in patients with philadelphia chromosome-positive advanced myeloid leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1002\/ajh.26175","article-title":"An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am J Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2237790","DOI":"10.1080\/16078454.2023.2237790","article-title":"Combination of venetoclax with BCR::ABL1 tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias","volume":"28","author":"Zou","year":"2023","journal-title":"Hematology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3390\/cancers14071805","article-title":"Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Group for research on adult acute lymphoblastic leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph+ acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR::ABL1 tyrosine kinase inhibitor combinations: outcome in patients with philadelphia chromosome-positive advanced myeloid leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/ijms25010484","article-title":"Venetoclax and hypomethylating agent combination in myeloid malignancies: mechanisms of synergy and challenges of resistance","volume":"25","author":"Mishra","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.3324\/haematol.2019.229997","article-title":"CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax","volume":"105","author":"Mattes","year":"2020","journal-title":"Haematologica."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41375-025-02539-0","article-title":"CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents","volume":"39","author":"Reuvekamp","year":"2025","journal-title":"Leukemia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.medj.2024.07.018","article-title":"Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed","volume":"5","author":"Suo","year":"2024","journal-title":"Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-24-1332","article-title":"Homoharringtonine added to venetoclax and azacitidine improves outcome and mitigates genetic impact in relapsed\/refractory aml: a multicenter cohort study","volume":"31","author":"Yu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J Hematol Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2003","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107665","DOI":"10.1016\/j.leukres.2025.107665","article-title":"Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion","volume":"151","author":"Shi","year":"2025","journal-title":"Leuk Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e96576","DOI":"10.7759\/cureus.96576","article-title":"Mixed-phenotype acute leukemia transforming into acute myelomonocytic leukemia (AML M4): a case report and therapeutic challenges","volume":"17","author":"Alhayek","year":"2025","journal-title":"Cureus."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1182\/blood-2011-08-372508","article-title":"Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1788083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:00:26Z","timestamp":1788274826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1788083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1788083"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1788083","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1788083"}}